Literature DB >> 25081182

An updated natural history model of cervical cancer: derivation of model parameters.

Nicole G Campos, Emily A Burger, Stephen Sy, Monisha Sharma, Mark Schiffman, Ana Cecilia Rodriguez, Allan Hildesheim, Rolando Herrero, Jane J Kim.   

Abstract

Mathematical models of cervical cancer have been widely used to evaluate the comparative effectiveness and cost-effectiveness of preventive strategies. Major advances in the understanding of cervical carcinogenesis motivate the creation of a new disease paradigm in such models. To keep pace with the most recent evidence, we updated a previously developed microsimulation model of human papillomavirus (HPV) infection and cervical cancer to reflect 1) a shift towards health states based on HPV rather than poorly reproducible histological diagnoses and 2) HPV clearance and progression to precancer as a function of infection duration and genotype, as derived from the control arm of the Costa Rica Vaccine Trial (2004-2010). The model was calibrated leveraging empirical data from the New Mexico Surveillance, Epidemiology, and End Results Registry (1980-1999) and a state-of-the-art cervical cancer screening registry in New Mexico (2007-2009). The calibrated model had good correspondence with data on genotype- and age-specific HPV prevalence, genotype frequency in precancer and cancer, and age-specific cancer incidence. We present this model in response to a call for new natural history models of cervical cancer intended for decision analysis and economic evaluation at a time when global cervical cancer prevention policy continues to evolve and evidence of the long-term health effects of cervical interventions remains critical. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  decision analysis; human papillomavirus; mathematical models; uterine cervical neoplasms

Mesh:

Year:  2014        PMID: 25081182      PMCID: PMC4143081          DOI: 10.1093/aje/kwu159

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  42 in total

1.  Benefits and risks of HPV testing in cervical cancer screening.

Authors:  Philip E Castle; Hormuzd A Katki
Journal:  Lancet Oncol       Date:  2010-01-18       Impact factor: 41.316

2.  Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006.

Authors:  Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

Review 3.  Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling.

Authors:  Sue J Goldie; Jeremy D Goldhaber-Fiebert; Geoffrey P Garnett
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

4.  A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion.

Authors:  Martyn Plummer; Mark Schiffman; Philip E Castle; Delphine Maucort-Boulch; Cosette M Wheeler
Journal:  J Infect Dis       Date:  2007-04-16       Impact factor: 5.226

5.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.

Authors:  Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg
Journal:  Lancet Oncol       Date:  2008-04-11       Impact factor: 41.316

6.  Multiparameter calibration of a natural history model of cervical cancer.

Authors:  Jane J Kim; Karen M Kuntz; Natasha K Stout; Salaheddin Mahmud; Luisa L Villa; Eduardo L Franco; Sue J Goldie
Journal:  Am J Epidemiol       Date:  2007-05-25       Impact factor: 4.897

7.  Cost-effectiveness of HPV 16, 18 vaccination in Brazil.

Authors:  Sue J Goldie; Jane J Kim; Katie Kobus; Jeremy D Goldhaber-Fiebert; Joshua Salomon; Meredith K H O'shea; F Xavier Bosch; Silvia de Sanjosé; Eduardo L Franco
Journal:  Vaccine       Date:  2007-06-15       Impact factor: 3.641

8.  Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.

Authors:  Ruanne V Barnabas; Päivi Laukkanen; Pentti Koskela; Osmo Kontula; Matti Lehtinen; Geoff P Garnett
Journal:  PLoS Med       Date:  2006-04-04       Impact factor: 11.069

Review 9.  Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  BMC Infect Dis       Date:  2009-07-29       Impact factor: 3.090

10.  Prevalence and determinants of HPV infection among Colombian women with normal cytology.

Authors:  M Molano; H Posso; E Weiderpass; A J C van den Brule; M Ronderos; S Franceschi; C J L M Meijer; A Arslan; N Munoz
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

View more
  38 in total

1.  The Need for Societal Investment to Improve Cervical Cancer Outcomes in Nigeria: A commentary.

Authors:  Jonah Musa
Journal:  Afr J Reprod Health       Date:  2017-12

2.  Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.

Authors:  Nicole G Campos; Philip E Castle; Thomas C Wright; Jane J Kim
Journal:  Int J Cancer       Date:  2015-05-21       Impact factor: 7.396

3.  Development and Calibration of a Mathematical Model of Anal Carcinogenesis for High-Risk HIV-Infected Men.

Authors:  Emily A Burger; Michael A Dyer; Stephen Sy; Joel M Palefsky; Alexandra de Pokomandy; François Coutlee; Michael J Silverberg; Jane J Kim
Journal:  J Acquir Immune Defic Syndr       Date:  2018-09-01       Impact factor: 3.731

4.  Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.

Authors:  Jane J Kim; Emily A Burger; Stephen Sy; Nicole G Campos
Journal:  J Natl Cancer Inst       Date:  2016-10-18       Impact factor: 13.506

5.  The Cost-Effectiveness of Cervical Self-Sampling to Improve Routine Cervical Cancer Screening: The Importance of Respondent Screening History and Compliance.

Authors:  Emily A Burger; Stephen Sy; Mari Nygård; Jane J Kim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-09-13       Impact factor: 4.254

6.  National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States.

Authors:  David P Durham; Martial L Ndeffo-Mbah; Laura A Skrip; Forrest K Jones; Chris T Bauch; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

7.  Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.

Authors:  Kine Pedersen; Emily A Burger; Stephen Sy; Ivar S Kristiansen; Jane J Kim
Journal:  Gynecol Oncol       Date:  2016-08-17       Impact factor: 5.482

8.  Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.

Authors:  Jane J Kim; Nicole G Campos; Stephen Sy; Emily A Burger; Jack Cuzick; Philip E Castle; William C Hunt; Alan Waxman; Cosette M Wheeler
Journal:  Ann Intern Med       Date:  2015-09-29       Impact factor: 25.391

9.  Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.

Authors:  Carolyn M Rutter; Jane J Kim; Reinier G S Meester; Brian L Sprague; Emily A Burger; Ann G Zauber; Mehmet Ali Ergun; Nicole G Campos; Chyke A Doubeni; Amy Trentham-Dietz; Stephen Sy; Oguzhan Alagoz; Natasha Stout; Iris Lansdorp-Vogelaar; Douglas A Corley; Anna N A Tosteson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-17       Impact factor: 4.254

10.  Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.

Authors:  Kine Pedersen; Emily A Burger; Mari Nygård; Ivar S Kristiansen; Jane J Kim
Journal:  Eur J Cancer       Date:  2018-01-12       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.